Nureca Ltd
Incorporated in 2016, Nureca Ltd is in the business of Home Healthcare and Wellness Products.[1]
- Market Cap ₹ 264 Cr.
- Current Price ₹ 277
- High / Low ₹ 344 / 198
- Stock P/E 24.8
- Book Value ₹ 208
- Dividend Yield 0.00 %
- ROCE -0.90 %
- ROE -1.12 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company is expected to give good quarter
Cons
- The company has delivered a poor sales growth of 1.98% over past five years.
- Company has a low return on equity of -3.23% over last 3 years.
- Earnings include an other income of Rs.9.07 Cr.
- Working capital days have increased from 255 days to 434 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|
| 62 | 99 | 213 | 256 | 111 | 92 | 110 | 143 | |
| 53 | 90 | 152 | 200 | 126 | 102 | 117 | 136 | |
| Operating Profit | 9 | 10 | 62 | 56 | -15 | -10 | -8 | 7 |
| OPM % | 15% | 10% | 29% | 22% | -13% | -11% | -7% | 5% |
| 0 | 0 | 3 | 8 | 7 | 11 | 12 | 9 | |
| Interest | 0 | 1 | 2 | 1 | 0 | 0 | 1 | 2 |
| Depreciation | 0 | 0 | 0 | 1 | 2 | 2 | 2 | 2 |
| Profit before tax | 9 | 9 | 62 | 61 | -11 | -3 | 1 | 13 |
| Tax % | 30% | 26% | 26% | 26% | -23% | -30% | 37% | |
| 6 | 6 | 46 | 45 | -8 | -2 | 1 | 11 | |
| EPS in Rs | 6,230.00 | 6,400.00 | 46.37 | 44.96 | -8.25 | -1.79 | 0.85 | 10.82 |
| Dividend Payout % | 0% | 0% | 4% | 7% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 2% |
| 3 Years: | -25% |
| TTM: | 51% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 284% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -10% |
| 1 Year: | -2% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 8% |
| 3 Years: | -3% |
| Last Year: | -1% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.01 | 0.01 | 10 | 10 | 10 | 10 | 10 | 10 |
| Reserves | 8 | 15 | 153 | 193 | 185 | 183 | 184 | 189 |
| 0 | 10 | 4 | 4 | 3 | 3 | 5 | 5 | |
| 15 | 9 | 19 | 12 | 8 | 10 | 11 | 21 | |
| Total Liabilities | 24 | 34 | 186 | 219 | 207 | 205 | 210 | 225 |
| 1 | 1 | 4 | 10 | 9 | 7 | 9 | 14 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 33 | 59 | 94 | 1 | 8 |
| 23 | 33 | 182 | 175 | 139 | 104 | 200 | 203 | |
| Total Assets | 24 | 34 | 186 | 219 | 207 | 205 | 210 | 225 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| 0 | -8 | 35 | 1 | 10 | -3 | -19 | |
| -0 | -0 | -110 | -3 | -16 | 18 | 8 | |
| -0 | 8 | 92 | -7 | -2 | -1 | -0 | |
| Net Cash Flow | 0 | -0 | 17 | -9 | -8 | 14 | -11 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 52 | 47 | 0 | 4 | 14 | 6 | 11 |
| Inventory Days | 123 | 93 | 135 | 174 | 167 | 186 | 214 |
| Days Payable | 89 | 33 | 32 | 13 | 24 | 31 | 35 |
| Cash Conversion Cycle | 87 | 107 | 103 | 165 | 157 | 161 | 190 |
| Working Capital Days | 45 | 85 | 61 | 109 | 156 | 176 | 434 |
| ROCE % | 57% | 67% | 33% | -6% | -4% | -1% |
Documents
Announcements
-
Disclosures under Reg. 10(7) of SEBI (SAST) Regulations, 2011
31 Jan - Report on buyback (Dec 18–24, 2025); promoters’ stake rose to 68.09%; 4,58,255 shares bought back.
-
Disclosures under Reg. 10(6) of SEBI (SAST) Regulations, 2011
28 Jan - Buyback (Dec18-24, extinguished Jan7) reduced shares by 4,58,255; promoters' stake rose to 68.09%.
-
Disclosures under Reg. 29(1) & 29(2) of SEBI (SAST) Regulations, 2011
28 Jan - Promoters' stake increased from 64.97% to 68.09% after Dec 18–24, 2025 buyback; shares extinguished Jan 7, 2026.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
20 Jan - Nureca Limited has informed regarding Newspaper Publication.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
19 Jan - Nureca Limited has informed regarding Newspaper Publication.
Annual reports
Concalls
-
Jan 2026TranscriptAI SummaryPPT
-
Jan 2026TranscriptAI SummaryPPT
-
Oct 2025TranscriptAI SummaryPPT
-
Jul 2025TranscriptAI SummaryPPT
-
May 2025TranscriptAI SummaryPPT
-
Jan 2025TranscriptAI SummaryPPT
-
Oct 2024TranscriptAI SummaryPPT
-
Aug 2024TranscriptAI SummaryPPT
-
May 2024TranscriptAI SummaryPPT
-
Feb 2024TranscriptAI SummaryPPT
-
Nov 2023TranscriptAI SummaryPPT
-
Aug 2023TranscriptAI SummaryPPT
Business Overview:[1][2]
NL is a digitally first, consumer healthcare company with presence in categories such
as home diagnostics, wellness devices, and personal fitness equipment under brands like
Dr Trust and Dr Physio. The company has 277+ Active SKUs, and 7 New Products were launched during Q1FY26